Yu Xin, Zhang Jian-ning, Liu Rui, Wang Ya-ming, Sun Jun-zhao, Qi Shu-bin, DU Ya-nan, Wang Hong-wei, Zhao Hu-lin, Liu Zong-hui
Department of Neurosurgical, Navy General Hospital of People's Liberation Army, Beijing 100037, China. Email:
Zhonghua Wai Ke Za Zhi. 2013 Jul;51(7):631-5.
To evaluate the long-term results of combination treatment with Gamma Knife radiosurgery and stereotactic intracavitary brachytherapy for mixed cystic and solid craniopharyngiomas.
Sixty-seven consecutive patients with mixed cystic and solid craniopharyngioma treated by Gamma Knife radiosurgery combined with stereotactic brachytherapy from October 1996 to December 2005 were selected for retrospective analysis. The inclusion criterion was the patients who survived for at least 5 years after combined treatment. There were 39 male and 28 female patients and the mean age was 31.5 years (ranged from 3 to 70 years). The clinical evaluations including neurological, neuro-ophthalmological, and neuro-endocrinological examinations, assessment of comprehensive quality of life and neuroimaging examinations were performed periodically. The actuarial survival rates and the mean survival time were calculated by using Kaplan-Meier product limit method. The rates were compared using the χ(2) test.
Follow-up period varied from 60 to 168 months, with an average of 114 months. The tumor response rate gained from combination treatment with Gamma Knife radiosurgery and stereotactic intracavitary brachytherapy for predominantly solid and cystic craniopharyngiomas were 10/12 and 90.9% respectively, and 89.6% in all. Mean survival after combination treatment was (110 ± 9) months. The mean survival of patients with predominantly solid and cystic craniopharyngioma were (97 ± 12) months and (120 ± 14) months and the actuarial 10-year survival rates were 7/12 and 69.1%. There was no statistics difference in tumor response rate and 10-year survival rate between 2 groups of patients with predominantly solid and cystic craniopharyngioma. The actuarial 5-, 6-, 7-, 8-, 9- and 10-year survival rates were 90.5%, 85.7%, 83.3%, 76.4%, 69.4% and 60.0% respectively. The decreased visual acuity had improved in 68.3% at 6 months postoperatively and in 70.0% in long term results. Comprehensive quality of life in long term follow-up of 67 patients was excellent in 28 cases(41.8%), good in 19 cases(28.4%), fair in 17 cases(25.4%) and poor in 3 cases(4.5%), respectively. The side effects that occurred 6 to 12 months after treatment were worsening of visual acuity (4 patients), dysfunction of hypothalam (4 patients) and third nerve palsy was found in 1 patents 5 years after treatment. The rate of complications was 13.4%.
Combination treatment with Gamma Knife radiosurgery and stereotactic intracavitary brachytherapy is highly effective and safety in the treatment of mixed cystic and solid craniopharyngiomas.
评估伽玛刀放射外科与立体定向腔内近距离放射治疗联合应用于混合性囊性及实性颅咽管瘤的长期疗效。
选取1996年10月至2005年12月期间接受伽玛刀放射外科联合立体定向近距离放射治疗的67例连续性混合性囊性及实性颅咽管瘤患者进行回顾性分析。纳入标准为联合治疗后存活至少5年的患者。其中男性39例,女性28例,平均年龄31.5岁(3至70岁)。定期进行包括神经、神经眼科和神经内分泌检查、综合生活质量评估及神经影像学检查等临床评估。采用Kaplan-Meier乘积限界法计算精算生存率和平均生存时间。采用χ(2)检验比较发生率。
随访时间为60至168个月,平均114个月。伽玛刀放射外科与立体定向腔内近距离放射治疗联合应用于以实性为主和囊性为主的颅咽管瘤的肿瘤缓解率分别为10/12和90.9%,总体为89.6%。联合治疗后的平均生存时间为(110±9)个月。以实性为主和囊性为主的颅咽管瘤患者的平均生存时间分别为(97±12)个月和(120±14)个月,精算10年生存率分别为7/ (12) 和69.1%。以实性为主和囊性为主的两组颅咽管瘤患者的肿瘤缓解率和10年生存率无统计学差异。精算5年、6年、7年、8年、9年和10年生存率分别为90.5%、85.7%、83.3%、76.4%、69.4%和60.0%。术后6个月视力下降改善率为68.3%,长期结果中改善率为70.0%。67例患者长期随访的综合生活质量分别为优28例(41.8%)、良19例(28.4%)、中17例(25.4%)、差3例(4.5%)。治疗后6至12个月出现的副作用为视力恶化(4例)、下丘脑功能障碍(4例),1例患者在治疗5年后出现动眼神经麻痹。并发症发生率为13.4%。
伽玛刀放射外科与立体定向腔内近距离放射治疗联合应用于混合性囊性及实性颅咽管瘤的治疗具有高效性和安全性。